Tetrathiomolybdate Combination Therapy for Viral ARDS Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 and influenza lack effectiveness in preventing the progression to acute respiratory distress syndrome (ARDS) and associated organ damage, particularly due to intravascular inflammation and procoagulant mechanisms leading to lung and heart failure.
Innovation Solution
A combination therapy using Diethylcarbamazine (DEC) or Zileuton as a 5-lipoxygenase inhibitor and tetrathiomolybdate (TTM) as a copper chelator, along with other drugs like Fluvoxamine, Ivermectin, Curcumin, and Prostacyclin Analogues, to inhibit chemotaxis, decrease vascular permeability, and reduce inflammatory mediator production, thereby targeting intravascular inflammation and procoagulant mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard treatments (low volume mechanical ventilation and conservative fluid management) are used for ARDS, then patient survival is maintained with minimal intervention, but the treatment fails to prevent progression to fully developed ARDS and associated organ damage
Solution Approach 1:
The patent applies preliminary action by administering copper chelators and 5-lipoxygenase inhibitors to patients at risk for developing ARDS, before the syndrome fully manifests. This early intervention targets the inflammatory and procoagulant mechanisms that drive ARDS progression, preventing the transition from early infection to fully developed ARDS and organ failure
Solution Approach 2:
The patent changes the therapeutic parameters by introducing copper chelation therapy and 5-lipoxygenase inhibition as new treatment modalities. This shifts the treatment approach from mechanical support to biochemical intervention, targeting the underlying inflammatory pathways and copper-dependent processes that drive disease progression
2Reliability
If anti-viral medications and vaccinations are used to stop virus spreading, then viral replication is reduced, but they fail to address the inflammatory and procoagulant mechanisms causing organ damage
Solution Approach 1:
The patent applies universality by developing a treatment regimen that addresses multiple pathological mechanisms simultaneously - copper-dependent inflammation, leukotriene-mediated vascular permeability, and procoagulant activity. This multi-functional approach can be applied across different disease stages and viral etiologies, making it versatile for treating COVID-19, influenza, and other viral infections that progress to ARDS
Solution Approach 2:
The patent uses copper chelators and 5-lipoxygenase inhibitors as intermediary substances that mediate between the viral infection and the resulting organ damage. These agents intervene in the inflammatory cascade by blocking copper-dependent enzymatic processes and leukotriene production, thereby preventing the progression from viral replication to tissue injury
3Reliability
If early intervention with therapeutic drugs is administered within the 2-7 day window, then progression to ARDS can be prevented, but the current lack of effective drugs limits treatment options
Solution Approach 1:
The patent merges multiple therapeutic agents into a combined regimen - copper chelators (such as tetrathiomolybdate), 5-lipoxygenase inhibitors (such as zileuton and montelukast), and anticoagulants. This combination therapy addresses multiple pathological pathways simultaneously, creating a more effective treatment than any single agent alone during the critical early intervention window
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy effectively inhibits the progression to ARDS by reducing lung and heart damage, preserving endothelial cell function, and preventing systemic inflammation, offering a safer treatment option that can be used alongside other therapies.
Implementation Method 1
tetrathiomolybdate (TTM) as a copper chelator
Implementation Method 2
Diethylcarbamazine (DEC) or Zileuton as a 5-lipoxygenase inhibitor
Data Source
AI summary
A method of treating a Corona Virus, e.g., COVID 19, Influenza and ARDS, is provided. A copper chelator including a tetrathiomolybdate salt is administered with a 5-lipoxygenase enzyme inhibitor, e.g., Diethylcarbamazine or Zileuton. Baicalin, Bufalin, Quercetin, Curcumin, inhibitors of NF-kappaB, the Applied Therapeutics Aldose Reductase inhibitor AT-001, Sulforaphane or Fluvoxamine can be additional drugs. This is an intervention treatment of a Corona Virus, e.g., COVID 19, ideally in the second phase of the disease, in the Pulmonary Phase, preferably prior to the Hyper-Inflammation Phase, as a preventive therapy to reduce the need for a ventilator and increase the survival of hospitalized patients. The two-drug treatment combination aims at preventing ARDS and other organ damage caused by COVID 19 infection by targeting the intravascular disease component. Tetrathiomolybdate in oral and Intravenous forms combined with the other drugs in intravenous or inhaled forms are designed to treat advanced forms of these diseases.